RealFeedApp betaTop science & technology news, November 10, 2026
- CTEV passed Phase 2a clinical trial in ten adult patients
Humacyte launched a Phase 2a clinical study of its coronary tissue-engineered vessel, CTEV, in ten patients undergoing bypass surgery. The FDA approved the investigational new drug application in July 2026, with patency assessed at two months and follow-up up to three years.
- Researchers replaced Cas9 with Cas12a to destroy DNA
The study replaced Cas9 with Cas12a to deliver a DNA-destroying enzyme to tumor cells once specific mutations are detected. This mechanism converts a detection event into a guided missile-like destruction of the cell's genetic material.
- AlphaProof Code proves Signal protocol security
Google DeepMind researchers used the AlphaProof Code framework to formally verify the underlying code of the Signal protocol. This marks the first time AI agents have mathematically proven key security properties of the actual code protecting billions of private conversations.
- 418 bugs found in Python
Opus 5.5 agents rewrote CPython internals in Lean, verifying 4,071 functions and uncovering 418 bugs, including 55 that crash the interpreter.
- vLLM handles millions of requests on GPUs
The vLLM team demonstrated high-throughput inference techniques using prediction pipelines and KV cache optimization to maximize GPU utilization.
- New system saves millions in token expenses
Amazon replaced Claude Sonnet 4.6 with Strands Decider for internal ticketing, maintaining 98% accuracy while drastically reducing token expenses.
- Oyster secures $60m funding and begins trials with a light-penetrating tau degrader
The startup Oyster raised $60 million and initiated clinical trials for a therapy using a molecule that crosses the blood-brain barrier to degrade tau protein.
- GenDB-V is 22 times faster
The GenDB-V system, which uses AI to generate code, achieved 22–61x speedups over DuckDB and Umbra. The fully formally verified system addresses the crisis of overfitting on benchmarks.
- Anthropic valued at $1.404 trillion
The company offers 825 million Class A shares to raise between $57.75 billion and $64.35 billion. A listing at the top of the price range would result in a fully diluted valuation of $1.404 trillion.
- Base editing treatment freed sickle cell patients from severe pain
Beam Therapeutics announced positive results from a pivotal trial of its base editing treatment, which aims to precisely alter individual nucleotides to address sickle cell disease symptoms.
- Study reveals risks of early death
New research suggests chemotherapy may accelerate biological aging beyond chronological age and increase the risk of earlier death from other causes. This is the first study to estimate the lifetime balance of curing breast cancer versus potential acceleration of biological aging using population-based simulation modeling.
- New workflow detects trace cancer DNA in plasma samples
The new duplex chemistry workflow detects trace circulating tumor DNA (ctDNA) by confirming base calls on complementary strands. Kits are expected to ship in Q1 2027.
- The MemoryDojo benchmark covers four subject domains
The MemoryDojo study found that malicious commands received in one session can be stored in agent memory and executed in later sessions. The benchmark covers 155 multi-session trajectories across four domains to measure poisoning impact.
- US ecommerce stores get Business Agents
OpenAI launches beta Business Hub for managing company information. US-based businesses can use Business Agents to interact with users via ecommerce and online services.
- Gene gda-1 encodes an intestinal guanine deaminase
Researchers found that genes horizontally transferred from bacteria in Caenorhabditis elegans encode enzymes regulating purine levels. Mutations in these genes cause xanthine stone formation, mimicking human xanthinuria.
- Adobe introduces on-brand graph creation in Firefly
Adobe is launching proactive AI agents in Photoshop, Premiere, and Firefly that automatically gather context for work. The company also launched Builder, a new prototyping tool in private beta.
- f-LENNS reduces hallucination in reconstructed brain images
The f-LENNS framework, trained on synthetic data, enhances spatial resolution in standard fMRI without retraining and reduces hallucinations. It enables accurate visualization of mesoscale brain organization from conventional scans.
- Protein expression profile differs between BPD and control groups
Analysis of 79 postmortem brain samples revealed distinct protein expression patterns between individuals with BPD and controls.
- Interactive connectors link AI to your applications
Anthropic launched new artifact types for Claude Sheets and Whiteboards and upgraded interactive connectors to integrate AI with apps via the Model Context Protocol.
- Gemini 4 Carbon is now available to developers and scientists
The model is designed for complex multi-step tasks, including coding and open scientific discovery, utilizing larger token volumes for deep reasoning.
